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As alternatives to well-established lines such as Vero or BHK cultures new designer cells are 
under consideration for vaccine production. A very successful example for a designer cell is 
Crucells’ human PER.C6 currently either used or evaluated for production of vaccines against 
Ebola, malaria, West Nile disease and influenza. ProBioGen AG has created avian cells 
(AGE1.CR and AGE1.CR.pIX) from duck retina using adenovirus type 5 E1 and pIX genes as 
potential candidates for vaccine production. These avian cells grow in suspension in serum free 
(SFM) or protein free medium (PFM) and can be productively infected with different influenza 
strains. Typically, modified vaccinia virus Ankara (MVA) is produced in chicken embryo fibroblasts 
(CEF), as apart from BHK cells not many other cells are able to replicate MVA. In both avian cells 
(CR and CR.pIX) MVA can also be produced.  
When evaluating new cells for vaccine production metabolic data together with cell density and 
virus titers need to be characterized for different cultivation conditions such as media, cultivation 
vessels or infection conditions to identify optimal settings. Here, we present data for cultivation of 
CR and CR.pIX cells in roller bottles and small scale bioreactors (STR, wave). Surprisingly, pIX 
appears to impact glutamate and pyruvate metabolism of CR cells. Differences between the two 
cell lines in metabolism (changes in consumption or release of glucose, lactate, glutamine, 
ammonia, glutamate and other amino acids) together with cell density in different media will be 
discussed. Virus replication and yields will be compared to adherent Vero and MDCK cells (for 
influenza) as well as BHK suspension cells (for MVA). Furthermore, various influenza virus 
strains (influenza A (H1N1, H3N2), influenza B) will be compared and glycosylation fingerprints of 
the HA proteins will be shown.  
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Influenza is a global disease causing several million infections in humans every year. One of the 
most effective methods in controlling seasonal influenza epidemics is prophylactic vaccination, 
which requires fast, effective and reliable processes to produce large amounts of vaccine doses 
every year. Traditionally, the production of human influenza vaccines is based on the growth of 
viruses in embryonated chicken eggs. However, several limitations are associated with this 
method including low efficiency, limited scalability and potential allergic reactions induced by egg 
proteins. Hence, mammalian cell culture based vaccine production has been developed requiring 
new downstream process strategies for virus purification.  
The presented study focused on the development of a pseudo-affinity capture step for Madin 
Darby canine kidney (MDCK) cell culture derived influenza viruses by sulphated cellulose 
membranes. Extensive purification studies were done using different influenza virus strains 
including two strains from the season 2007/2008 (A/Wisconsin/67/2005 (subtype H3N2), 
B/Malaysia/2506/2004) and A/Puerto Rico/8/34 (subtype H1N1). Viral recoveries based on 
hemagglutination activity (HA), as well as reduction of host cell dsDNA and total protein were 
directly compared to results obtained with commercially available cation exchange membrane 
adsorbers and cellufineTM sulphate. With the modified cellulose membranes a higher viral product 
recovery was achieved than with cellufineTM sulphate and the cation exchange membrane 
adsorbers, respectively.  
Due to the low back pressure and fast binding kinetics allowing significantly higher flow rates, 
sulfated cellulose membranes are economically favorable over column based media such as 
cellufineTM sulphate.  
Therefore, sulphated cellulose membranes seem to be an attractive tool for industrial 
downstream processing of influenza virus in vaccine production. They might even have the 
potential to replace column based matrix cellufineTM sulphate, which is commonly used for virus 
purification.  
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Insect cell system to protein expression has been intensely used for the protein production 
recombinant. However, in some cases, low expression amounts have limited the industrial 
production of some proteins of interest. Futhermore, apoptosis death has limited the recombinant 
protein production. Thus being, one of the forms of to increase the cellular productivity would be 
to inhibit or to attenuate this cellular death. Recently we have demonstrated that the presence of 
an potent antiapoptotic protein in Lonomia oblique hemolymph showing that hemolymph 
supplementation can extend the cell culture viability through apoptosis prevention. Has been 
reported that mitocondria has one important action in the apoptosis control process, being that 
mitocondrial membrane permeabilization (MMP) can be an important stage in this process. MMP 
associated m) eΨor not with the loss of the potential electrochemical of the mitocondria (∆ 
alteration of the matrix is responsible for the intermembran protein release (e.g. cytochrome c, the 
AIF, etc) of citosol. As result of this release, some protein (caspases) and DNases are activated 
and the death process one becomes irreversible. We have observed that the addition of Lonomia 
obliqua hemolymph to the culture lead to a prolongation of the cellular life (3-4 days) allowing a 
higher recombinant protein production for baculovírus system in Sf-9 cells or human HEK-293 
cells ( more than twice in both system). To identifie the protein with this biological effect, 
hemolimph was fractionated by ionic exchange and gel filtration chromatographies. Apoptosis 
death was induced by 500 μm of t-BHP or 600 μm of H202. The presence of apoptosis was 
characterized by FACS, microscopy electronic and agarosis DNA eletroforesis and the potential 
m) was determined by JC-1, Hoechst 33324Ψelectrochemical of the mitocondria. (∆ and 
DIOC6(3). Citocrome C was identified in cytosol by one antibody anti cytochrome. Addition of 
hemolymph to the apoptosis induced culture avoid the m) suggesting that the antiapoptoticΨcell 
death and the cells showed a high (∆ effect of this protein can be by it’s action in mitocondria 
membrane, avoiding the lost of the membrane permeability and the cytochrome C liberation .  
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Virus-like particles are widely used in vaccine development due to their safety, immunogenicity 
and relative cost-effective production. Production of virus-like particles can be carried out in 
various expression systems like yeast, insect cells or plants. Expression of influenza proteins in 
insect cells leads to the formation of virus-like particles which are a promising vaccine candidate 
against pandemic and inter-pandemic influenza. We generated influenza virus-like particles by 
expression of influenza A virus derived proteins HA, NA and M1 by the baculovirus expression 
system. We also generated influenza virus-like particles by expression of all known influenza 
proteins except the PB1-F2 protein. As influenza virus-like particles are an interesting tool in 
recombinant antigen presentation we introduced different epitopes, e.g. from M. tuberculosis 
ESAT-6 into a specific site of the HA-ectodomain. In addition we alternatively tested plants to 
serve as a production system for virus-like particles. We cloned HA, NA and M1 using suitable 
expression cassettes into the pGreenII vector. Using A. tumefaciens for DNA-transfer we 
examined the transient expression of influenza proteins in N. benthamiana and the possibilities of 
formation of influenza virus-like particles, expressing HA, NA ad M1. Influenza virus antigens 
expressed in forage plants propose an interesting vaccine for oral mass immunizations of poultry. 
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Production of proteins for immunization needs post-translational modifications that are critical for 
antigenicity. Glycosylsation and correct folding are common related processes involved in the 
generation of a good quality protein. Therefore, eukaryotic hosts are indicated expression 
systems for the production of post-translation dependent proteins, as they have the appropriated 
cell machinery to protein maturation. Here we report the utilization of Drosophila melanogaster 
Schneider 2 (S2) cells and the Semliki Forest Virus (SFV) expression system to produce the 
rabies virus glycoprotein (RVGP). They represent different systems with advantages of 
generating high-level expression of functional membrane proteins, to be relatively easy and safe 
to handle and scalable. We have constructed gene vectors with or without the BiP signal (i) or the 
selection hygromycin gene (H) where the inserted RVGP gene is under the control of 
metalothionein (MT) or actin (Ac) promoter. After transfection S2MTiRVGP, S2MTiRVGP-H, 
S2MTRVGP, S2MTRVGP-H, S2AcRVGP and S2AcRVGP-H cell populations were selected and 
the expression of RVGP evaluated by FACS, ELISA, western-blotting. The ability of RVGP to 
produce antibodies was investigated by “in vivo” mouse immunization. The data showed a higher 
RVGP expression in S2MTRVGP-H cells (52 % of positive cells, 4 micrograms/1E7 cells). 
Parameters for storage, lysis and concentration of cells expressing the RVGP were studied for 
productivity evaluation and future purification. A protocol of cell preparation including cell freezing 
as dry pellet, cell thawing at 4ºC with Tris, NaCl, MgCl2, PMSF and cell lysis with the buffer 
containing NP-40 was chosen, since it fulfilled requirements of high RVGP detection, easiest and 
quick frozen and cost saving lysis buffer formulation. Selection of an adherent S2AcGPV2K cell 
population enabled us to enrich the RVGP expression from 0.5 to 3 micrograms/1E7 cells (30 to 
60 % of positive cells). Western blotting analysis showed a 65 KDa RVGP monomeric structure. 
High levels of antibodies against RVGP were found in immunized mice. The RVGP gene was 
also cloned into a pSFV expression vector. BHK-21 cells were electroporated with expression 
and helper RNA vectors and SFV-GPV particles were obtained. These were used to infect BHK-
21 cells and the RVGP expression was confirmed by western blotting, ELISA and cell 
immunofluorescence. These data show several steps of optimization for high RVGP expression in 
S2 cells, its synthesis in a high degree of quality and the RVGP expression in the SFV system. 
Supported by FAPESP, CNRS, CNPq, Fundação Butantan.  
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Ehrlichia ruminantium is an obligate intracellular pathogen and, as such, cell mediated immunity 
plays a key role in the control of bacterial replication and subsequent protection against 
heartwater. Thus, identification of antigens that preferentially activate T cells to proliferate and 
secrete IFN-gamma need to be evaluated as vaccine candidates. Previously a cocktail of four 
open reading frames were identified that induce IFN-gamma and 100% protection after needle 
challenge but only 20% protection after tick challenge in the field, when administered as a DNA 
vaccine in sheep. Considering that limited protection was obtained during a field vaccine trial our 
research is focused to improve this efficacy. Because secreted proteins are reported to be major 
targets in the specific immune response we hypothesise that they may be potential heartwater 
vaccine candidates. We selected five ORFs encoding secreted E. ruminantium proteins from the 
Welgevonden stock genome sequence using bioinformatics tools. The corresponding 
recombinant proteins were expressed in a bacterial expression system and assayed to determine 
whether they induce recall cellular immune responses in vitro. Only four recombinant proteins 
could be expressed. Significant proliferative responses were evident for 3/4 recombinant proteins. 
IFN-gamma production was determined using an ELISPOT assay and 3/4 recombinant proteins 
induced IFN-gamma production. Each recombinant protein had its own optimum concentration for 
inducing immune responses and the responses differed between animals. Thus these three 
proteins that induce proliferation and IFN-gamma production may be important in protection 
against heartwater and will be tested in future vaccine studies.  
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Cryo-transmission electron microscopy (cryoEM) provides a method for directly observing 
macromolecules in their native hydrated state, avoiding the artifacts associated with alternative 
preparation methods like negative staining. While cryoEM can provide invaluable data for sizing 
and structural analysis, this technology has not in the past been suitable as a standard 
characterization method. However, recent advances in microscope control and automation have 
streamlined cryoEM data acquisition and analysis and, in conjunction with an integrated 
database, the method now provides a controlled and routine process suitable for 
biopharmaceutical and biotechnology applications. We will provide an overview of cryoEM and 
demonstrate the advantages of the technique using specific examples. In particular, we will 
describe a collaboration with Merck & Co., on the characterization of a quadrivalent human 
papillomavirus VLP vaccine (Gardasil™). Automated cryoEM methods were used to accurately 
determine bulk size distributions of the VLPs assembled from four different serotypes. Particles of 
a specific size range were then selected and used to reconstruct three dimensional (3D) electron 
density maps of the VLPs. CyoEM imaging provides direct visualization of the particles in solution 
and the 3D reconstruction provides a comparison with theoretical and experimental models of the 
structure. CryoEM also provides very specific and accurate size analysis of the sample population 
and the ability to visualize aggregates within the sample. These data can be used to calibrate 
other bulk sample measurements, for example light-scattering.  
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Given the ability to efficiently transduce human dendritic cells, adeno-associated viruses are 
promising vaccine candidates. It is known, however, that the full utility of this class of vector has 
been hampered by the difficulty in producing high-titer AAV stocks. Since the ability to produce 
AAV vectors in insect cells was first described in 2002, a deeper understanding of the system has 
advanced the state of the art towards realizing the full potential of this system. Three 
baculovectors are used: BacRep, for the replication proteins; BacCap, for the structural proteins; 
and BacITR, for the AAV vector genome. The baculovectors were designed such that the Rep78 
gene, under the control of a ΔIE1 promoter, is expressed earlier and to a lesser extent than other 
AAV proteins in the system, whose expressions are driven by polyhedrin promoters. The flexibility 
that co-infection systems generally offer is restricted with this design, and the relative time of 
infection impacts the quantity of AAV vector produced. A delay in the addition of BacRep by 12 
hours results in a dramatic loss of AAV vector production. Both quantity and the time of addition 
of the BacITR affect AAV vector production the least, supporting that the availability of the 
“template” is not the bottleneck of the process. Increasing culture temperature increases the early 
production of Rep78 and Rep52, concomitant to a significant increase in AAV vectors produced. 
Given this understanding we have investigated production strategies at increased cell densities, 
which ensure the cells receive BacRep. Although specific cell productions is maintained up to 
~10x10^6 cells/ml using a medium renewal strategy, a fed-batch strategy, more amenable to the 
production at large scale allowed us to maintain the specific production up to ~8x10^6 cells/ml 
(650 ETU/cell). The current approach is based on combining an asynchronous/synchronous 
infection. This alternative strategy allows the propagation of one of the viruses (BacITR) from a 
low MOI. The other viruses are then added at a point when the primary virus has been amplified 
to the extent of being able to infect the complete culture. Given an initial MOI of 0.1 pfu/cell, the 
optimal time of addition of the other viruses was 27 hpi, which gave an increase in volumetric 
production of 237% compared to cultures co-infected with all three baculovectors at MOIs of 3 
each. These results provide more incentive to use the baculovirus/insect cell derived AAV vectors 
for large clinical investigations.  
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In recent years, gene therapies and DNA vaccines have captivated the scientific and medical 
communities with their potential to yield new, specific, and safe treatments for many devastating 
diseases. Plasmid DNA-based therapies represent a substantial portion of current research 
efforts. As these therapies move into clinical trials and toward FDA approval, the demand for 
pure, high-quality plasmid DNA will increase. Current plasmid production processes almost 
exclusively use common laboratory host strains of Escherichia coli K-12 like DH5alpha. These 
strains have been designed for cloning or recombinant protein production, and as a result have 
been heavily mutagenized. This mutagenesis could potentially affect cell survival and metabolite 
utilization when compared to wild type cells. Successful large-scale manufacture of plasmid DNA 
requires robust host cells that yield high biomass and minimize the production of impurities.  
This work will engineer a wild-type strain of E. coli for enhanced plasmid DNA yield using 
systematic gene knockouts. The recA and endA genes will be mutated first, as disruption of these 
genes is known to improve plasmid stability and maintenance. With most of its natural survival 
mechanisms still intact, we predict that this new strain will be better equipped to withstand the 
burdens of high-density cell culture and overproduction of plasmid DNA. The plasmid production 
capacity of the engineered strain will be compared to that of both wild-type E. coli and a common 
laboratory strain. Preliminary results comparing the plasmid production of wild-type and 
laboratory strains suggest that strains with a genotype similar to wild-type may yield higher 
concentrations of plasmid DNA.  
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DNA vaccines and gene medicines, derived from bacterial plasmids, are emerging as an 
important new class of pharmaceuticals. They may allow the manufacturer to bypass years of 
development for the production of efficacious vaccines, and literally create new vaccine entities 
and mass produce vaccines in 2-3 weeks for rapid deployment against new biological agents. 
However, the challenges of producing plasmid DNA at an industrial scale are well known: low 
bioreactor yields, scaling up alkaline lysis, clearance of host RNA and chromosomal DNA, and 
avoiding the use of animal sourced products. This limits their utility to meet cost and capacity 
needs for existing plasmid applications, or to rapidly produce kilograms of plasmid DNA for 
pandemic vaccination.  
The development of an inducible fed-batch fermentation process that dramatically increases 
volumetric yield and specific plasmid yield, while maintaining or enhancing plasmid integrity has 
been the first achievement toward these goals. This inducible process utilizes commercially 
available media that we designed specifically for plasmid production. The process consists of an 
initial biomass accumulation phase, followed by a plasmid accumulation phase. The plasmid is 
stably maintained at low levels during a period of nutrient restricted growth and reduced 
temperature (30°C), and then the temperature is increased (37-42°C) to induce plasmid 
amplification. Typically, the specific plasmid yield increases over a period of up to 15 hours 
following temperature up-shift. Volumetric yields exceeding 2.1 g plasmid DNA/L have been 
achieved with this process, and this process has been successfully scaled up for GMP 
production.  
To address downstream purification challenges, we have successfully demonstrated feasibility of 
a cost effective and simple purification process that eliminates costly alkaline or heat lysis steps 
and the associated toxic waste streams. We developed autolytic E. coli host strains that express 
endolysin after the temperature increase in the fermentation. In the autolytic purification process, 
lysis is performed at moderate temperatures and without the addition of lysozyme.  
The overall result is a rapid deployment plasmid production system linking autolytic plasmid 
purification to our existing fermentation platform to facilitate immediate production of a variety of 
plasmid DNAs for pandemic applications. The major benefits of this production platform are 
speed, safety, simplicity, scalability and transferability to existing manufacturing facilities in 
developed and emerging countries.  
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Plasmid DNA is an emerging experimental vaccine produced in E. coli that was initially targeted 
for viral diseases. Unlike traditional protein vaccines when average dose is micrograms, the 
average dose of pDNA is milligrams; therefore, production yields are critically important for the 
future development of this vaccine. The E. coli strains currently used for pDNA production, JM109 
and DH5a, are both suitable for production of stable pDNA due to the deletion of recA and endA, 
but at the same time, these two E. coli K strains are sensitive to growth conditions such as high 
glucose concentration. E. coli BL21 is less sensitive to growth conditions than E. coli JM109 or 
DH5a, it grows to higher densities and due to its active glyoxylate shunt and anaplerotic pathways 
is not sensitive to high glucose concentration. This strain is used intensively for recombinant 
protein production but not for pDNA production because of its inability to produce stable pDNA. 
To adapt E. coli BL 21 for stable pDNA production, the strain was mutated by deleting both recA 
and endA, and proper growth and production strategy was developed. Volumetric production 
values exceeding 2 grams per liter were obtained using glucose as carbon source. The produced 
plasmid, which was constructed for HIV clinical purpose, was found to be identical in its 
properties to the plasmid currently produced by E. coli DH5a.  
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The high immunogenicity of peptides displayed in dense repetitive arrays on virus-like particles 
makes recombinant VLPs promising vaccine carriers. We describe a platform for vaccine 
development based on the VLPs of RNA bacteriophage MS2. It serves for the engineered display 
of specific peptide sequences, but should also allow the construction of random peptide libraries 
from which specific binding activities can be recovered by affinity selection. Peptides representing 
the V3 loop of HIV gp120 and the ECL2 loop of the HIV coreceptor, CCR5, were inserted into a 
surface loop of MS2 coat protein. Both insertions disrupted coat protein folding and VLP 
assembly, but these defects were efficiently suppressed by genetically fusing coat protein's two 
identical polypeptides into a single-chain dimer. The resulting VLPs displayed the V3 and ECL2 
peptides on their surfaces where they showed the potent immunogenicity that is the hallmark of 
VLP-displayed antigens. Experiments with random-sequence peptide libraries show the single-
chain dimer to be highly tolerant of 6-, 8- and 10-amino acid insertions. Not only do MS2 VLPs 
support the display of a wide diversity of peptides in a highly immunogenic format, but they also 
encapsidate the mRNAs that direct their synthesis, thus establishing the genotype/phenotype 
linkage necessary for recovery of affinity selected sequences. The single-chain MS2 VLP 
therefore unites in a single structural platform the selective power of phage display with the high 
immunogenicity of VLPs.  
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Rotavirus-like particles (RLPs), candidate vaccines against Rotavirus disease, can be produced 
in insect cells by co-infection of baculoviruses coding for VP2 and VP6 for double-layered RLP 
2/6 as well as for VP2, VP6 and VP7 in triple-layered RLP 2/6/7. Analytical methods currently 
used for virus-like particles (VLPs) characterization include SEC-HPLC, TEM, SDS-PAGE and 
Western Blot. However, these methodologies are either time-consuming, have little sensitivity, 
and thus are semi-quantitative or involve a significant amount of sample. Moreover, they do not 
give information on the particle’s stoichiometry and assembly, which are important issues for 
improving VLP yield.  
In this work novel techniques were applied for RLP 2/6 and RLP 2/6/7 characterization. SDS-
capillary gel electrophoresis (SDS-CGE) was successfully used for quantitative and qualitative 
characterization of RLPs in terms of detecting the presence and relative proportion of VPs for 
quality control purposes. The method demonstrated to be accurate for apparent molecular weight 
estimation and allowed evaluation of VP7’s degree of glycosylation. Its precision is sufficient for 
detection of VP6/VP7 ratio differences between different samples as well as for protein 
quantification.  
Another extremely useful technique to characterize VLPs is dynamic light scattering (DLS), which 
enables measurement of zeta potential, size and molecular weight. The average diameters of 
RLP 2/6 and RLP 2/6/7 were 50 and 80 nm, respectively. Several physical-chemical conditions 
(pH, ionic strength, temperature and chelating agent concentration) were used for size and zeta 
potential measurement. Besides giving valuable information on RLPs stability and disassembly, 
DLS also enabled the plot of a titration curve for pI calculation, which was 2.7 (RLP 2/6/7).  
Using both methods, stoichiometry, assembly and disassembly kinetics of RLPs are possible to 
evaluate and quantify. 
Poster Number 13  
HOST STRAIN INFLUENCES ON SUPERCOILED PLASMID DNA PRODUCTION IN E. COLI; 
IMPLICATIONS FOR EFFICIENT DESIGN OF LARGE SCALE PROCESSES.  
Sin Yee Yau, The Advanced Centre for Biochemical Engineering, Dept. of Biochemical 
Engineering, UCL.  
Torrington Place, London, WC1E 7JE, UK  
T: +44 (0)2076794410, F: +44 (0)2079163943, s.yau@ucl.ac.uk  
John Ward, Dept. Biochemistry and Molecular Biology, UCL.  
Eli Keshavarz-Moore, The Advanced Centre for Biochemical Engineering, Dept. of Biochemical 
Engineering, UCL.  
With many gene based vaccines/therapies in early development, there is a growing need for 
quick and effective methods to obtain relatively large amounts of supercoiled plasmid DNA. 
Whilst much effort has been directed towards the downstream processing, there is much room for 
improvements at the earlier stages of production namely the cell host/plasmid selection where the 
choice of the E. coli host strain used to propagate the product containing-plasmid may have 
sizeable influence on the quality and quantity of the purified DNA. This would influence both 
production as well as the downstream operations.  
In this investigation, a systematic approach has been conducted to carry out experiments with 17 
E. coli strains and 3 plasmids to determine the influence of the host strain on the quantity and 
quality of DNA obtained, particularly supercoiled DNA. The strains selected range from well 
known commercial strains to the lesser used ones from the early era of microbiology. The data 
obtained from this investigation can provide an effective tool in selecting a host strain for a 
specific plasmid-based product, potentially reducing manufacturing costs by aiding the 
productivity of the system and improving the downstream processing stages. The study shows 
that the choice of host strain strongly affects the total yield of plasmid DNA. In cultures containing 
two relatively similar-sized plasmids and with similar high copy numbers some strains gave a 
higher yield with one plasmid (e.g. MG1655 with gWiz) and not with the other (e.g. MG1655 with 
pSVbeta). On the other hand, there were strains that grew well and provided consistent high 
yields of plasmid DNA and also SC-DNA for both these plasmid cultures and these were 
DH5alpha, BL21 DE3, TG1 and HB101 at 10ml and 100ml scales. All tested strains propagating 
a large plasmid (20kb) generally produced lower plasmid DNA yields than obtained from cultures 
producing smaller plasmids (5-7 kb). The results also show that the presence of certain host 
strain mutations previously reported to aid the quality of plasmid DNA such as endA and recA, 
does not always guarantee high supercoiled DNA yield. Higher specific growth rates of some 
strains did not affect the level of supercoiling but did influence the total DNA plasmid yield, 
making an important finding in the design of fermentation strategy. 
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Adenoviruses have transitioned from tools for gene replacement therapy to bona fide vaccine 
delivery vehicles. They are attractive vaccine vectors as they induce both innate and adaptive 
immune responses in mammalian hosts. Currently, adenovirus vectors are being tested as 
subunit vaccine systems for numerous infectious agents ranging from malaria to HIV-1. To meet 
the growing market requirements and reduce the final cost of vaccine production, large amounts 
of adenoviral vectors need to be generated by designing efficient and scaleable processes.  
Adenovirus production is currently limited by reduced cell-specific productivity observed at high 
cell density infection. This so-called “cell density effect” is probably due to nutrient limitations 
and/or metabolite inhibition. Though various feeding strategies have been explored to overcome 
this effect, only limited success has been achieved. The exact nature of the limitations remains 
unknown. To better understand these limitations, we first compared the performances of three 
culture media (CD 293, Ex-Cell 293 and NSFM13) for growth of 293SF cell (clone of HEK-293) 
and for production of adenovirus. Ex-Cell 293 promoted the best cell growth, however, the cells 
grown in this medium produced low virus yields. In contrast, CD 293 did not support 293SF cell 
growth after few cell passages while it was the best medium for virus production. The nutritional 
requirements of 293SF cells appear to be different between cell growth and virus production 
phases.  
The cell density effect was prevalent in cultures using the above media, however the decline in 
the virus production was far more drastic (98%) in NSFM 13 culture than in other two cultures 
when the cell density at infection was increased from 0.5 to 3x106 cells/mL. The attribution of 
nutrient limitation and metabolite accumulation to the cell density effect was investigated by 
supplementing potential limiting nutrients or inhibitory metabolites (lactate and ammonia) to 
infected cultures. Lactate and ammonia generated during virus production contributed only 
partially (about 30% decline) to the observed cell density effect, while nutrient limitation was 
primarily responsible for the drastic decline in the virus production when NSFM 13 was used as 
production medium. The portion of cell density effect associated with nutrient limitation can be 
minimized through supplement of nutrients or national medium formulation.  
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Vaccine studies using Adenovirus (Ad) vectors have been hampered due to the barrier of pre-
existing immunologic responses against Ad in many cases. This has resulted in a variety of 
protocols designed to overcome this limitation. In an attempt to avoid the barrier of pre-existing 
immunity, we have evaluated a novel [E1-, E2b-] Ad serotype 5 (utilizing the E.C7 cell line for viral 
packaging) vector vaccine to assess its effectiveness as a potential vaccine platform as 
compared to the currently utilized [E1-] Ad5 based platforms. The new human [E1-, E2b-] Ad5 
vector vaccines have several advantages. Most importantly, Ad viral DNA replication is 
significantly diminished due to the removal of the E2b region. This results in at least a 10,000-fold 
reduction in the production of Ad late gene products. The decrease in late gene products reduces 
the potential of Ad encoded viral proteins from impacting host immune responses by decreasing 
antigenic competition from the Ad genes and enhanced transgene expression resulting in 
increased immunologic stimuli.  
The present studies were designed to construct and test the effectiveness of an HIV-1 vaccine 
platform based on the new [E1-, E2b-] Ad vector platform in vivo. [E1-] Ad and [E1-, E2b-] Ad 
vector vaccines having Gag, Pol or Nef inserts were used. Ad vaccines were tested for their 
potential to induce HIV antigen memory CMI responses and antibody in a prime and boost 
protocol in Ad-naïve and Ad-immune mice. We report that the Ad5 vectors are equally 
immunogenic in Ad naïve mice. [E1-, E2b-] Ad vector vaccines had statistically greater 
immunogenic propensity in Ad immunized mice, as compared to [E1-] Ad vector vaccines. Thus, 
the [E1-, E2b-] Ad vector vaccines were successfully employed in a prime-boost protocol in both 
Ad naïve and Ad immune mice, whereas [E1-] Ad vectors were only effective in Ad naïve. The 
[E1-, E2b-] Ad vaccines induced significantly greater numbers of antigen specific CD8+ T-cells 
and CD4+ T-cells. We hypothesize that the greater number of CD4+ T-cells was a result of higher 
concentrations of IL-2 induced by [E1-, E2b-] Ad vector vaccines. These results indicate that one 
can immunize Ad naïve and Ad immune vaccinees using the new [E1-, E2b-] Ad vector vaccine 
platform in a prime-boost manner.  
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E. coli has been widely used as a host for the production of recombinant proteins. In this 
presentation, two examples of high cell density recombinant E.coli BLR fermentation will be 
discussed. In the first study, the pBAD expression system was used since it affords a simple 
method for regulating protein production to maximize yield. However, the araBAD promoter is 
catabolite repressed if glucose is present above certain concentrations in the culture medium 
during induction with arabinose. To more efficiently utilize arabinose, simultaneously feeding 
arabinose and glucose was investigated. By optimizing the feeding and induction strategies, 
arabinose usage was reduced significantly, resulting in high cell densities (OD of about 100) and 
recombinant protein production of approximately 2 g/L.  
In the second study, the T7 expression system (pET vector) was used, which requires IPTG for 
protein induction. It was discovered that isoleucine was required when chemically defined 
medium was used during fermentation of E. coli BLR (DE3) host strains. To achieve high cell 
densities, isoleucine together with glucose was fed during fermentation. Using design of 
experiments (DOE) methodology, induction OD, IPTG concentration, and post-induction feed 
rates were assessed. Induction OD was the only significant factor in determining maximal protein 
production. Final OD of about 100 with recombinant protein titers of approximately 2 g/L were 
achieved after optimization. 
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Helper-dependent adenoviral vectors (HDV), devoid of viral coding genes, are attractive vehicles 
for vaccination. They do not trigger the adaptive immune response, a major drawback in vaccine 
efficacy. Despite an increasing demand for this vector, production is still non-efficient as a result 
of an empirical process. A HEK293 cell line is usually co-infected with HDV and a first generation 
vector called Helper Virus (HV). A recombinase system is generally used to restrict HV 
packaging. In an attempt to improve HDV productivity while decreasing HV contamination, 
strategies to manipulate the stoechiometry of HDV components were evaluated. The multiplicity 
of infection (MOI) of both viruses was a simple parameter not only to improve HDV productivity 
but also to limit HV contamination. Using a quantitative PCR assay to compare HDV and HV 
titers, we found that HDV titer was dependent on the co-infection ratio whereas HV titer was only 
related to the MOI of HV. Consequently, HV contamination could be dramatically high when high 
MOI of HV is used (up to 60 times more HV than HDV with MOI HV 10). At optimal co-infection 
conditions, 2x108 infectious HDV/mL were obtained with only 1% HV contamination. Delaying HV 
infection did not result in higher HDV and/or lower HV titers. Together with the use of an efficient 
recombinase system, co-infection with optimal amount of viruses guarantees the quality of HDV 
stock before purification.  
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The attenuated vaccine against yellow fever (YF) virus produced in embryonated eggs at 
FIOCRUZ (Brazil) has been available for decades. This vaccine has been used for human 
immunization with an excellent history of efficacy and safety. However, in the latest years, the 
occurrence of adverse events associated with the 17D and 17DD substrains indicated the need 
for developing technologies for the production of an inactivated vaccine. With this aim, the use of 
continuous cell lines for production of the antigen offers advantages over viruses grown in 
embryonated eggs. A major advantage is the production of virus in large scale under controlled 
conditions (pH, temperature, dissolved O2).  
Vero is a continuous, adherent cell line, which has been recommended by the World Health 
Organization for the production of human vaccines. Commercial processes using this cell line for 
vaccine production are based on its culture on microcarriers in stirred systems. The aim of this 
study was the development of an efficient cell culture process and an adequate infection strategy 
for propagating the yellow fever virus in Vero cells using stirred bioreactors.  
Using the best conditions determined for cell propagation and viral infection, employing a serum-
free medium, very high virus titers (108 pfu/mL) were obtained, indicating that the methodology 
developed in this work is efficient and could be employed in a process for the production of yellow 
fever virus. Analysis of the antigenic properties of the 17DD virus by an enzyme-linked 
immunoassay showed no difference between the virus cultivated in serum-containing and in 
serum-free medium. In addition, SDS-PAGE analysis of the supernatant obtained from infected 
cell cultures confirmed a drastic reduction in the protein content of samples of the YF virus 
cultivated in serum-free medium. Thus, the development of a cell culture process for propagating 
the yellow fever virus in Vero cells grown in serum-free conditions can represent an important 
step towards the production of a new, inactivated vaccine against yellow fever.  
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Sleeping Sickness is an emergent disease and an important cause of mortality in sub-Saharan 
Africa. The annual reported number of infected people is 30 to 50 000 but unfortunately this 
estimative is considered to be the tip of the iceberg as the actual number could be as high as 300 
000 cases per year. The current drug regimens are unacceptable due to serious side effects, so 
the development of new therapeutics, as a vaccine, is urgent.  
Ten DNA vaccine prototypes for African Trypanosomosis were constructed encoding ISG and 
TSA genes from Trypanosoma brucei containing different targeting protein sequences to the 
major processing of antigens pathways: (1) LAMP-1 signal targets the protein to the lysosomes 
(ISG-LAMP, TSA-LAMP); (2) E1A directs the protein to the ER (E1A-ISG, E1A-TSA) (3) secretion 
signal promotes the protein secretion (Sc-ISG, Sc-TSA) (4) E1A and LAMP combined (E1A-ISG-
LAMP, E1A TSA-LAMP).  
CD1 mice were immunised with 50µg of each candidate vaccine and blood samples were taken 
for the determination of anti-ISG and anti-TSA antibodies by ELISA assays. Animals were 
sacrificed 28 days post-immunization and axillary and popliteal lymph nodes were taken to 
perform immunohistochemistry analysis and mRNA extraction for cytokine quantification (IL 2, IL 
4, IL 6, IL 10, IFNg and TNFá). ISG-LAMP, TSA LAMP and ISG-E1A presented higher 
expression levels for most of the cytokines tested. Haematoxylin and eosin histological sections 
of right popliteal lymph nodes taken from mice immunized with ISG LAMP and E1A-ISG-LAMP 
have shown the typical characteristics found in activated lymph nodes (such as lymphatic nodules 
with germinal centres and lymph vessels with lymphocytes). Cell-mediated immunity was also 
determined through the DTH response measured by the footpad-swelling test. The immunised 
CD1 mice have received a trypanosome lysate on the right footpad 14 days post immunization 
(left footpad was injected with saline) and the footpad’s thickness was monitored at 24 and 48 
hours after injection. At 24h the footpad thickness of mice injected with ISG LAMP was 
significantly higher than the control.  
The study allowed us to select the most promising vaccines (ISG- LAMP, TSA LAMP and E1A-
ISG) that will be used in challenge assays to determine its effectiveness on the survival rates of 
infected mice.  
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DNA vaccination has matured to the point where a number of products should be hitting the 
market in the wake of the first veterinary DNA vaccines approved in 2005. Apart from their 
potential to prevent and treat infectious and acquired diseases, DNA vaccines offer advantages 
such as the rapid and generic manufacturing, good stability at high and low temperatures and low 
cost. The design and large scale production of plasmid DNA (pDNA), the active component of a 
DNA vaccine, are two key aspects underlying the successful development of a DNA vaccine.  
We have developed a patented process based on hydrophobic interaction chromatography (HIC) 
for the production and purification of pDNA vectors. Comparison of this method with an isolation 
process based on a glass fiber fleece matrix shows that the purification method used can strongly 
affect transfection efficiency of cultured CHO cells. Although quality analysis by standard 
analytical techniques did not detect significant differences between plasmids purified by the two 
methods and no differences on pDNA copy number in transfected cells were measured, an 
increase in mRNA copies (2.2-fold) and also in the reporter protein was found in cells transfected 
with HIC-purified plasmids. Circular dichroism analysis and SDS-PAGE indicate that these 
differences should be ascribed to trace amounts of E.coli proteins which inhibit transcription 
and/or mRNA maturation and stability. 
Nuclease degradation of DNA vaccines after delivery and during trafficking to the nucleus is a 
major barrier to gene expression and consequently to the elicitation of immune response. Our 
approach to reduce this problem relies on the construction of pDNA variants that are more 
resistant to nuclease action. This was achieved by modifying the polyadenylation and origin of 
replication in a model plasmid backbone. Although those regions contain non-B DNA secondary 
structures which facilitate the binding of specific proteins, our studies indicate that in the case of 
the origin of replication, nuclease resistance and transfection efficiency can be improved 2.5-fold 
and 1.5 fold, respectively, by replacing as few as 7 nucleotides without loss of functionality. In 
conclusion, the choice of plasmid vector sequences is important, not only for mRNA 
maturation/stability, but also for pDNA resistance, and should thus be taken into consideration 
when designing and evaluating pDNA vectors.  
Moreover, we have some evidence that the use of plasmids which are more resistant to 
nucleases is likely to have a positive impact in downstream processing and product shelf stability. 
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Group A rotavirus is the main cause of neonatal diarrhea in bovines and porcines. Vaccination 
has proven to be helpful for the prevention of this pathology, which causes important economic 
losses. Several groups have shown that virus like particles (VLP) inoculated into pregnant 
animals induce high antibody responses in mammary secretions; calves fed with colostrum or 
milk from vaccinated animals are protected from diarrhea following rotavirus challenge. Two 
proteins, VP7 and VP4, on the external viral capsid carry type-specific antigens and are 
responsible for the dual rotavirus classification into G (glycoprotein) and P (protease sensitive) 
serotypes/genotypes, respectively. Genotyping has been preferred to serotyping, due to its high 
sensitivity and use of universal reagents. Over 15 G and 26 P types have been identified to date. 
Genotyping of group A rotavirus is an essential tool for epidemiological studies of rotaviruses and 
is also important for vaccination, as it has been shown that protection between genotypes is 
limited. Therefore, it is necessary to incorporate the predominant genotypes in vaccines for a 
specific region to confer optimal passive immunity to calves. No previous reports exist on the 
group A rotavirus genotypes in Mexican bovine cattle. The goal of this study was to determine the 
genotypes G and P of group A rotavirus detected in fecal samples from calves in Mexico. One 
hundred twenty-eight fecal samples from calves with diarrhea were collected between 2005 and 
2006 from 26 dairy and/or beef cattle herds located in 10 regions of Mexico. Rotavirus group A 
was confirmed prior to genotyping by a rapid immunoassay for detection of VP6 rotavirus antigen. 
Genotyping was corroborated by sequence analysis. Rotavirus was identified in 15.6% of liquid 
stool samples. Calves born from cows vaccinated against G6, P[1] genotype (commercial 
vaccine) were affected by the G10, P[11] genotype. These results show that protection between 
genotypes was limited. The genotypes found were: G10, P[11] (67%); G6, P[5] (25%) and G10, 
P[5] (8%). These results show a clear relationship between genotype and species, as these 
combinations are commonly found in bovine rotavirus. It was also found that the commercial 
vaccine containing genotypes G6, P[1] provides partial heterotypic immunity against the G10, 
P[11] genotype. The genes isolated from the samples have been used for the production of VLPs 
using the insect cell-baculovirus expression vector system (IC-BEVS), or yeast. This is the first 
approach towards the development of a recombinant rotavirus veterinary vaccine in México.  
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Peste des Petits Ruminants virus (PPRV) is the causative agent of a highly contagious and fatal 
disease of sheep and goats and some small wild ruminant species that presents a significant 
economic impact in African and Asian countries.  
Currently the best strategy to control PPR is by vaccination with an attenuated strain produced in 
Vero cells. However, this cell line is anchorage dependent which can limit the scalability of the 
production process, as microcarrier technology is required. This work reports on the comparison 
of 293 cells, which are able to grow in single cell suspension using serum free media, with Vero 
cells for the production of PPRV. Similar volumetric productivities were achieved for both cell 
lines, namely 106 TCID50/mL, even when using low MOIs like 0.001.  
Moreover, being thermal stability a critical issue for vaccine delivery in developing countries, 
different formulations were tested and the effect of stabilizers, such as sucrose and trehalose 
were evaluated. The thermal inactivation of PPRV produced with the two cell lines in static 
conditions showed that virus produced in 293 cells were slightly less stable than those produced 
in Vero cells. A liquid formulation composed of a Tris buffer supplemented with trehalose was 
tested permitting a half-life of one month at 4ºC and 21 hours at 37ºC for virus produced in Vero 
cells.  
A good candidate formulation (Tris/trehalose formulation) was obtained for the current PPR 
vaccine without the need of lyophilization. This constitutes the first report on a PPR candidate 
vaccine produced in suspension culture with serum free media. Although more studies are 
necessary to optimize the production and minimize the viral infectivity losses, the results present 
herein constitute valuable information on the development of a large-scale cell culture process for 
PPR vaccine.  
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CervarixTM is a vaccine protecting against ‘high-grade’ cervical intraepithelial neoplasia and 
cervical cancer that are caused by the human papillomavirus (HPV) types 16 and 18. This 
vaccine is a suspension for injection that contains purified L1 proteins of HPV-16 and HPV-18 
assembled as virus-like-proteins (VLPs) combined with the AS04 adjuvant system.  
The thermal stability of CervarixTM was evaluated in three different studies that assessed: (1) the 
long-term stability which establishes the stability of the vaccine under proposed storage 
conditions following testing at various time points over the entire targeted shelf life period, (2) the 
accelerated stability which provides useful support data for establishing the expiration date and 
reveals the pattern of degradation under extreme storage conditions and (3) whether accidental 
exposures to conditions other than those proposed for long-term storage (e.g., during 
transportation) are deleterious to the product (transport test). The thermal stability was evaluated 
by monitoring the potency, the purity and the quality of the vaccine using physicochemical and 
immunological methods, such as the in vitro and in vivo potency.  
The long-term stability study showed that the vaccine is stable for the proposed 36-month shelf 
life when stored at +2°C to +8°C. The accelerated stability study showed that the vaccine is 
stable after storage for 7 days at 37°C without any pattern of product degradation. The transport 
test study showed that the vaccine is stable when exposed 7 days at 37°C after 9 months storage 
at +2°C to +8°C followed by a further storage for 27 months at +2°C to +8°C. Further data 
showed that CervarixTM is also stable when exposed 14 days at 25°C after 9 months storage at 
+2°C to +8°C followed by a further storage of 27 months and when exposed 30 days at 25°C 
after 11 months storage at +2°C to +8°C.  
Through the evaluation of immunological and physico-chemical stability-indicating parameters, 
CervarixTM is shown to be stable for 3 years under proposed storage conditions, under 
accelerated and extreme storage conditions as well as when accidentally exposed to conditions 
other than those proposed for long-term storage. The excellent thermal stability of CervarixTM is 
therefore compatible with worldwide supply of the vaccine.  
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To increase process yields in virus vaccine production in mammalian cell culture high cell 
densities are of prior interest. As an example we investigate an influenza vaccine production 
process [1]. Madin Darby canine kidney cells (MDCK) were cultivated on Cytodex1 microcarriers 
and later infected with influenza A virus. To achieve maximum productivity in such a process one 
has to verify that specific virus productivities should remain unchanged with increasing cell 
densities. In high-density cell cultures process parameters such as medium and oxygen supply 
also have to be considered. Simpson et al. [2] reported for a hybridoma cell line in mAb 
production that the amount of apoptotic cells increased due to several stress factors, i.e. under 
elevated oxygen partial pressure.  
Additionally, apoptosis is induced in the host cell during influenza virus infection (Takizawa et al. 
[3]). The virus induced apoptosis plays a crucial role during influenza virus infection as shown by 
Ludwig et al. [4]. Therefore, an investigation concerning the correlation between oxygen partial 
pressure induced apoptosis and virus replication during vaccine manufacturing has been carried 
out.  
Here, we present results obtained for high-density cell culture in small scale bioreactors. Cell 
numbers of 6.0 to 8.0 x 10 6 cells/mL were achieved in cultivations with microcarrier 
concentrations of 10 g/L. Cultivations at 40 % of air saturation and above 150 % of air saturation 
will be compared with respect to cell numbers on microcarriers, virus titres, level of apoptosis 
(TUNEL assay), and glycosylation of viral haemagglutinin proteins (capillary gel electrophoresis–
laser induced fluorescence (CGE - LIF)). First results indicate that apoptosis induced by elevated 
oxygen partial pressure can be beneficial for increasing virus yields.  
[1] Genzel et al.; 2004. Vaccine 22: 2202-2208  
[2] Simpson et al.; 1997. Biotechnology and Bioengineering 54: 1- 16  
[3] Takizawa et al.; 1993. Journal of General Virology 74: 2347 - 2355  
[4] Ludwig et al.; 2006. Cellular Microbiology 8(3): 375 - 386  
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Optimisation of rotavirus-like particle (RLP) production in insect cells is extremely complex. 
Multiplicity of infection (MOI), individual protein production (VP2, VP6 and VP7) and correspondent 
assembly into a triple layered particle (RLP) are major challenges for the upstream processing. 
Concomitantly, the downstream processing of RLPs faces several setbacks due to the complexity 
of the cell cultured bulk imposing a number of purification steps. Thus, strategies to suppress 
product-derived contaminants (trimers of VP6 and double layered particles – DLP) negatively 
impacting the overall process were designed based on novel mathematical and analytical tools. 
Such a rational approach integrating up- and downstream phases will be shown to improve global 
yields.  
To maximise product synthesis, the starting point consisted in evaluating the effect of MOI on 
final VP2 protein synthesis (used as a model for the remaining VPs). A stochastic/structured 
mathematical model developed in our group, combining an explicit stochastic infection process 
with intracellular mass action kinetics, was used. Final productivities were shown to be a 
compromise between high intracellular VP2 templates, obtained at high MOIs, and high infected 
cell densities, obtained at low MOIs. In fact, an optimal midterm MOI between 0.01 and 1 pfu.cell-
1 maximised process productivity. This strategy, further applied to the remaining VPs, will allow 
the establishment of optimal operational conditions for maximisation of RLPs production yields 
confirming the relevance of mathematical models in process development. Moreover, these 
results highlight the relevance of having accurate analyticals for viral stock titers estimation as 
MOI variations may compromise process optimisation. Several titration methods were compared. 
The techniques that better combined all important variables (accuracy, cost per titration, titration 
time and labor intensity) and therefore proved reliable for titer estimation were the TCID50, MTT 
and flow cytometric assays with intra-variabilities and costs per titration of 19% and 13.5€, 
respectively.  
Complementarily to this upstream optimisation, the design of an efficient downstream process 
route is equally important. A novel strategy using anion-exchange membrane chromatography 
(SartobindTM D membrane adsorber from Sartorius Stedim Biotech) was evaluated as these 
permitted high fluxes, rapid processing, little buffer consumption and a validation-free 
environment. Screening studies performed to elucidate the effect of the ionic strength and the pH 
of the equilibration buffer on the RLP capture efficiency allowed for the definition of best 
operational conditions. Moreover, steric mass action formalism was implemented for the 
prediction of the adsorption/elution profile of RLPs demonstrating to be an important 
mathematical tool for process optimisation. At the end, global downstream processing yields were 
improved by 46%.  
Mathematical tools were here demonstrated to play a determinant role in optimising RLPs 
production. The predictive capacity of the models presented show their utility in both up- and 
downstream phases reducing labor time and process costs, and improving yields.  
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A cell culture based manufacturing process is highly desirable for influenza vaccine production, 
especially during a pandemic when an additional quantity of vaccine is demanded in a short 
period of time. Similar to seasonal influenza vaccine strains, pandemic influenza virus strains can 
also propagate in selected mammalian and avian cells. Seasonal influenza vaccines consist of 
three different seasonal strains which are selected each season based on the circulating 
influenza strains. Hence, one of our challenges is to develop a robust cell culture based platform 
process that will require only minimal process changes for any new seasonal virus strain and for 
future unknown pandemic influenza viruses.  
In this communication, we report our efforts in developing a cell culture based platform process 
for production of cold-adapted live attenuated influenza virus strains (FluMist®) using Madin 
Darby Canine Kidney (MDCK) cells. These cells were cultured on microcarriers in proprietary 
serum-free media and infected with influenza vaccine strains. Using this process, we consistently 
obtained infectious peak virus titers > 8.3 log10 Focus Forming Units per ml (FFU/ml) for the 
three 2007/2008 seasonal strains and representative prototype pandemic vaccine strains. 
However, we also observed that the overall range of peak titers spanned from 7 to 9 log10 
FFU/ml for influenza virus vaccine strains tested thus far. In order to reduce the variability in the 
peak titers obtained for different viruses and to improve the overall virus productivity, we 
evaluated several process improvement strategies. As reported by other authors, exchanging the 
cell growth medium (CGM) with fresh and leaner medium during infection greatly improve virus 
titers. Nevertheless, a systematic evaluation of all CGM components failed to identify the 
components that were fully inhibitory to virus replication, although some caused a delay in virus 
production. In addition, isolation of macromolecules secreted by MDCK cells in the 10-100 kDa or 
>100 KDa range were found not to inhibit virus replication. Trypsin-like activity was confirmed to 
be critical for influenza A viruses but not for influenza B viruses, but the optimal range of trypsin 
concentration seems to be dependent on the specific strain.  
In conclusion, our results provide critical insights regarding cell culture medium factors that affect 
influenza vaccine productivity, which can be used to guide medium/process optimization efforts 
and ultimately increase vaccine productivity.  
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Current influenza vaccines are manufactured using embryonated hens’ eggs. The potential 
occurrence of a pandemic outbreak of avian influenza might reduce or even eliminate the existing 
supply of eggs, leaving the human population at risk. Also, the current egg production technology 
is intrinsically cumbersome and not easily scalable to provide a rapid worldwide supply of 
vaccine.  
In this work, the development of a platform process for cell culture production of a cold-adapted 
live attenuated influenza vaccine using a novel disposable Single Use Bioreactor (SUB) is 
presented. The SUB is designed as a stirred tank reactor for animal cell culture, with PID control 
of pH, DO, agitation, and temperature, similar to traditional glass or stainless steel bioreactors. 
The main product contact component of the SUB is a disposable plastic bag, thus, eliminating the 
need for in-situ cleaning, cleaning validation and sterilization of culture vessels. In addition, it 
allows quick turn-around for bioreactor use, since a production run can be stopped and reinitiated 
in just a few hours.  
Influenza virus production was carried out at 25 to 30L scale in the SUB by growing Serum Free 
(SF) Madin-Darby Canine Kidney (MDCK) cells on microcarriers, in proprietary serum-free media 
and then infecting the cells with FluMist® vaccine strains. MDCK cell growth performance was 
evaluated in the SUBs and found to be affected primarily by the agitation rate. After optimization 
of various process parameters, the cell growth rates reached the same level as that in 3L glass 
bioreactors. Additional process parameter changes, particularly those affecting virus production 
conditions, resulted in high yield of all three 2006/2007 seasonal FluMist® virus strains: A/New 
Caledonia/20/99 (H1N1 strain), A/Wisconsin/67/05 (H3N2 strain) and B/Malaysia/2506/04 (B 
strain) with each strain producing peak infectious virus titers ≥ 8.6 log10FFU/mL in the SUB at 30 
L scale. This is equivalent to >1 million doses in a single reactor run (approximately 40 doses per 
mL of harvest fluid). The accelerated development of the above disposable platform has enabled 
the start of a GMP campaign in just 5 months from the initiation of the first SUB run performed at 
development stage, and to successfully produce influenza vaccine clinical trial material.  
In conclusion, these results demonstrate the ability of the developed platform process in SUBs to 
produce influenza virus vaccine at high titer, and also its suitability for rapid implementation in 
clinical material production settings under cGMP. 
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Triple-layered rotavirus-like particle (tlRLP) production requires the simultaneous recombinant 
expression of three proteins, VP2, VP6 and VP7. These proteins assemble into triple, double or 
single-layered RLP. Successful production and application of rotavirus-like particles as vaccines 
requires the differentiation and quantification of each of these structures, as complete tlRLP are 
needed for an adequate immune response during vaccination. In the past, we developed a 
method to quantify double-layered (dl) RLP utilizing gel-permeation chromatography. However, 
this method cannot be utilized to quantify and differentiate dlRLP and tlRLP, as their difference in 
size is only 5 nm. Here, we report the use of zone capillary electrophoresis to achieve this task. 
We were able to successfully separate and quantify both dlRLP and tlRLP. Detection limits of 1.6 
and 2.6 µg/mL were obtained for dlRLP and tlRLP, respectively. This methodology allows the 
precise determination of the amounts of each RLP that are used for immunization, permitting the 
establishment of more rigorous immunization protocols with RLP and evaluation of the outcome.  
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Heartwater, a tick-borne disease of domestic and wild ruminants, is caused by the intracellular 
rickettsia Ehrlichia ruminantium (ER), posing a major constraint to livestock production throughout 
sub-Saharan Africa and some Caribbean islands.  
Despite the recent advances in genomics towards the screening of novel antigens to be used as 
vaccine candidates against heartwater, it is clear that the genome sequence per se does not 
provide information regarding to the temporal expression and function of the genes that are 
transcribed. Thus, to investigate the presence of proteins in a given biological compartment, at a 
specific time and in a defined environment, proteome studies are required. Herein, we have 
studied the expression of several ER genes (map1, map1-2, map1-6, map1+1, map1-14 and 
cpg2) along the bacterial developmental cycle and attempted to compare protein expression 
profiles between ER elementary bodies (infectious, EB) and reticulate bodies (non-infectious, 
RB). For this, infected BAE cell monolayers were harvested at different times post-infection and 
total ER protein extracts were prepared. The antigen identification was performed using Western 
Blot and immunofluorescence techniques methodologies.  
We could identify 5 of 6 ER proteins initially proposed, i.e., MAP1, MAP1.6, MAP1.2, CpG2 and 
MAP 1.14. Interestingly, from 5 to 48 hpi, most of these antigens are not detected. This time 
window corresponds to the lag and early exponential phase of ER growth and, hypothetically, 
when the transition from EB to RB would occur. These proteins are detected again at approx 72 
hpi (which corresponds to the mid-exponential phase in ER growth development) and it is 
maintained until 120 hpi, when ER elementary bodies are released from the host cells. 
Furthermore, some of the expressed proteins were found to be glycosylated (MAP1 and MAP1-2) 
and MAP1 proteins appears to be organised as a trimeric form, which exists only in EB.  
From the results obtained herein, it was also clear that the developmental cycle of ER in BAE 
cells is an asynchronous process, resulting in a heterogeneous population of bacterial 
morphologies with different protein expression profiles. Furthermore, we have begun to identify 
what are likely to be significant proteins involved in the process of redifferentiation of RB into 
mature, infective EB, such as MAP1.  
Overall, this knowledge not only will contribute to a better understanding of heartwater pathology 
as it can provide additional information on potential immunogens to develop a more effective 
vaccine against heartwater.  
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The VSSP is a nano-particle obtained by incorporation of GM3 ganglioside into the outer 
membrane complex of Neisseria meningitides. This nano-formulation has showed an effective 
adjuvant capacity in the dendritic cell activation and generation of CTL response to peptide and 
protein antigen. In this study, we evaluated the physicochemical properties (ganglioside/protein 
ratio, protein profile, size distribution, and zeta potential) and biological activity the VSSP nano-
particle obtained by two different formulation processes using Dialysis and Ultrafiltration. The 
dialyzed VSSP showed a ganglioside/protein ratio of 1.04 with trimodal particle size distribution 
while VSSP obtained by ultrafiltration showed a ganglioside/protein ratio of 0.69 with monomodal 
particle size distribution. However, the size of the main peak was 24 nm in both conditions. The 
protein profile and antitumoral activity were also similar.  
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Chinese Hamster Ovary (CHO) cells have been successfully employed to manufacture not only 
glycosylated antibodies, growth factors, and enzymes, but also glycosylated protein subunit 
vaccines.  
In 1983, Genentech initiated the first human clinical trial of a therapeutic protein made in 
recombinant CHO cell culture. At the time, many viewed recombinant cell culture as a production 
method of last resort, certainly not one suitable to make a high-dose therapeutic. With low peak 
cell densities and low specific productivities in medium containing expensive animal-derived 
components, final product concentrations at harvest were low, typically below 1 mg/L. 
Furthermore, there were regulatory risks, as the safety of products from continuous aneuploid cell 
lines (like CHO) had yet to be established.  
Twenty five years later, recombinant CHO cell culture has emerged as one of the dominant 
methods for production of recombinant glycosylated proteins. The story behind this emergence 
should be viewed as one of the great case studies in new technology development.  
In this presentation, data from 25 years of clinical production is analyzed to derive the CHO cell 
culture equivalent of 'Moore's Law' for semiconductors. Cell culture engineers are pitted against 
semiconductor and agricultural engineers. Progress rates for firms new to the field are 
distinguished from the rates for experienced firms. For batch and fed-batch CHO cell cultures 
used for clinical production, titers at harvest for experienced firms have doubled every 2 -3 years. 
Progress rates are compared against the historical benchmarks for penicillin and used to estimate 
a future maximum titer of 20 g/L.  
Participants will be recruited for a new, parallel study regarding progress rates in the manufacture 
of viral vaccines.  
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Cell-culture-based processes are a suitable alternative for viral vaccine production since they 
provide several advantages over other manufacturing methods. Since Vero cells are currently 
considered an acceptable cell substrate to express a variety of viruses, we developed a virus 
production platform using Vero cells adapted to grow in suspension in a serum free medium. 
After adapting anchorage dependent Vero cells to grow as a free-cell suspension, the cell line 
was capable of proliferating in a chemically defined synthetic medium. The production yields of 
vesicular stomatitis virus, herpes simplex virus 1 and polio virus 1 were evaluated using batch 
cultures of adherent Vero cells growing in T-flasks and the cells growing in suspension in spinner 
flasks. The effects of the multiplicity of infection (m.o.i), harvesting time, cell concentration and 
use of serum were evaluated. Under optimized conditions, similar production yields were 
achieved with both systems. 
Perfusion cultures in a bioreactor were performed in serum free media. When cell density 
reached 1-2x107 cells/ml cultures were infected with vesicular stomatitis virus and polio virus 1. 
Infection with vesicular stomatitis virus at m.o.i = 0.02 resulted in a viral titer of 2x1010 TCID50/ml 
at 25 h post infection. The viral specific production was 4 times higher than the obtained in batch 
experiments. In addition, infection with polio virus 1 at m.o.i. = 0.5 produced a significant 30 fold 
increment in viral titer. 
These results constitute valuable information for the development of a low-cost large-scale 
process using a suspension culture of Vero cells for producing viral vaccines. 
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Safety testing of biopharmaceutical products is vitally important prior to administration of product 
to patients. However, speed from manufacturing of the drug to having it released and available for 
the clinic is also very important and anything that can be done to reduce this time is of benefit to 
both the Manufacturer and the patient. Mycoplasma testing is an important part of the safety 
testing for biopharmaceuticals and currently takes 28 days. This timescale is not conducive for 
obtaining the rapid lot release testing results needed for biopharmaceutical products having short 
shelf-lives or for which there is a high market demand. This article seeks to explain the 
advantages of a more rapid test that has been developed to meet the need for speed to market, 
but which provides the same confidence in the results and therefore the safety of the therapeutic. 
The decrease in time for a critical biosafety test brings huge advantages in manufacturing when 
rapid and accurate testing results are required for lot release testing, raw material testing and in-
process intermediate testing.  
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The dengue virus belongs to the <i>Flaviviridae</i> family and occurs in 4 different serotypes 
(dengue-1 to dengue-4). Dengue fever is an emerging disease that has experienced a significant 
worldwide increase in incidence in the last years, representing a public health concern in many 
tropical and subtropical countries. Among the diseases transmitted by mosquitoes, dengue is 
currently the most common worlwide, with approximately 100 million cases every year and a 
mortality rate of 2.5%. In spite of its impact on public health, no effective vaccine against dengue 
fever is yet available on the market.  
 
Vero cells are accepted for the production of human vaccines and are presently used in the 
commercial production of different vaccines, such as polio and rabies. However, one of the main 
regulatory concerns in this field is related to the use of animal serum and animal-derived 
components as culture medium additives. Therefore, in this work we compared the production of 
dengue-2 virus (DEN-2) in a serum-containing medium (DMEM + 5% fetal bovine serum) and in a 
commercial serum-free medium (VP-SFM, Gibco). A factorial statistical experimental design 
methodology was used to evaluate the influence of TOI (1-3 days) and MOI (0.002-0.02) on virus 
titer. Experiments were carried out both in T-flasks and in spinner flasks using Cytodex-1 
microcarriers, and virus titer was monitored for 7 days post-infection.  
 
The results showed that the influence of MOI and TOI on virus titer varies according to the culture 
medium used. In most experiments, DEN-2 virus titer presented an increasing trend in the whole 
evaluated period. However, for large MOI values (0.02), a maximum virus production was 
observed 5 days post-infection in the serum-free medium regardless of the time of infection, and 
in the serum-containing medium this peak at 5 dpi occurred only when a large MOI value was 
combined with a large TOI (3 days). For the serum-supplemented medium, the maximum virus 
titer obtained increased with both MOI and TOI values, whereas for the serum-free medium, virus 
titer increased with TOI but remained approximately constant with MOI in the range evaluated in 
this work. In general, the use of the serum-supplemented medium gave higher virus production 
under all conditions tested. The maximum DEN-2 titer was 4.93E+6 pfu/mL (6.69 in log scale) for 
the serum-supplemented DMEM medium, and 1.28E+6 pfu/mL (6.11 in log scale) for the serum-
free VP-SFM medium. 
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Anchorage-dependent cell lines, such as MDCK, MDBK, Vero, CEF, MRC5, HEK293, etc., are 
used in biotechnology industry to produce viral vaccines for prophylaxis and viral vectors for gene 
therapy. At industrial scale, these cells are either cultivated in static mode on multiplate systems 
(Cell Factories from Nunc, Cell Cube from Corning, etc.) or on microcarriers (porous or non-
porous) in suspension in stainless steel stirred-tank bioreactors. Multiplate systems are bulky and 
require lot of handling operations, whereas stainless steel bioreactors need cleaning and 
sterilization operations, expensive control validations and high capital investment. For all of the 
above reasons, the biopharmaceutical companies rely more and more on space and money-
saving disposable solutions.  
Today, disposable bioreactors are available at different scales, but usually, they are not well 
adapted to cultivation of animal cell immobilized on microcarriers when a perfusion process is 
needed because the traditional spin-filter approach cannot be employed.  
Herewith we are presenting the case study of cultivation of MDBK (producing BHV viruses) and 
Vero cells (producing Influenza viruses) cultivated on Cytodex-1 beads (at 6 g/L) inside a 
Nucleo™ bioreactor. We are comparing the results in cell growth and virus production between 
single-use and classical stirred tank reactors.  
The Nucleo culture bag reactor contains a non-invasive paddle mixing technology, a sparger fixed 
on the impeller and holds standard DO and pH probes. The perfusion was implemented using an 
Alternating Tangential Flow system (ATF, Refine Technologies) connected to the reactor, a 
system based on an external tangential flow screen filter and a diaphragm pump.  
After 7 days of cultivation, MDBK cell density has reached up to ca. 150 cells/bead in serum-
containing medium (5.8x106 cells/ml) and up to ca. 100 cells/bead for Vero in serum-free 
conditions. Cells have been infected at confluence, and have respectively produced 1.25x108 
Bovine Herpes Viruses/ml for MDBK cells and 3.5x107 Influenza Viruses for Vero cells (while 
control in STR reactor was 1.15x107 Influenza virus/ml).  
These cultivations have established the ability to cultivate immobilized cells in perfusion in a 
single-use bioreactor for the production of viral vaccines. The combination of these two 
technologies is attractive for vaccine manufacturing but will reach its full potential when 
disposable options will be available for the perfusion device as well as for the on-line probes.  
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We are exploring the interface between bionanotechnology and vaccine technology. We are 
developing a bionanotechnology platform that can deliver antigen and a danger signal to dendritic 
cells (DCs) that are resident within the lymph node. We engineered antigen-bearing nanoparticle 
vaccines with two novel features: lymph node-targeting and in situ complement activation. 
Following intradermal injection, interstitial flow transported our ultra-small nanoparticles (25 nm) 
highly efficiently into lymphatic capillaries and their draining lymph nodes, targeting half of the 
DCs there, whereas nanoparticles even 100 nm large were only 10% as efficient. Furthermore, 
we exploited a polyhydroxylated nanoparticle surface chemistry in order to potently activate the 
complement cascade via the alternative pathway. Complement-activating nanoparticles that 
reached lymph node spontaneously generated a danger signal in situ and potently activated DCs. 
With the model antigen ovalbumin conjugated to the nanoparticles, we demonstrated humoral 
immunity by measuring IgG antibody titers. The nanoparticle induced potent antibody levels 
similar to that of potent adjuvants such as aluminum salts and bacterial lipopolysaccharide (LPS). 
Furthermore, we demonstrated that antigen-bearing nanoparticles could also induce cellular 
immunity in a complement and lymph node targeting dependent manner. We characterized 
cellular immunity through measuring a Th1 biased response both on the DC and T cell level. 
Interleukin 12p40 (IL-12p40) is an essential cytokine secreted by DCs during Th1 activation. 
Following incubation with polyhydroxylated-nanoparticles pre-treated with serum, DCs produced 
high levels IL-12p40, approaching that of the potent Th1 activator LPS. Additionally, we show that 
complement-activating OVA-nanoparticles induce DCs to produce high expression of MHC I. 
Finally we demonstrate T cell memory of nanoparticle immunized mice through production of 
inflammatory cytokine interferon (IFN-γ) following re-exposure to an antigenic stimulus. One of 
the most difficult challenges in vaccine adjuvant technology is overcoming immunotoxicity, often 
due to overproduction of inflammatory cytokines. Therefore we tested the effect of complement-
activating nanoparticles on DCs to produce the pro-inflammatory cytokines TNF-α and IL-6. We 
observed that there were undetectable levels of both TNF-α and IL-6, indicating that while 
complement can activate DCs to mature and produce IL-12p40 but they do not stimulate strong 
pro-inflammatory cytokine expression such as the TLR activators LPS and CpG (unmethylated 
bacterial DNA).  
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During the recent couple of years the disposable bioreactor technology has taken the biotech 
community with storm. However, disposable bioreactors are still not commonly used for 
microcarrier cultivation, despite the fact that several of the most frequently used cell lines for 
industrial vaccine production are adherent, e.g. MDCK and Vero, and thus require microcarriers 
for large scale production.  
Here we demonstrate the use of Cytodex™ 3 microcarriers in a process for MDCK-based 
influenza virus production in a WAVE™ disposable bioreactor system. Attachment of cells to the 
microcarriers was performed in the WAVE CELLBAGTM using slow rocking during 3-4 hours, after 
which the rocking was gradually increased concomitant with the cell growth. Oxygen and pH were 
measured and controlled with a WAVEPODTM integrated controller. Key metabolites were 
measured throughout the process. When the cells were near confluence (approx. 106 cells/mL), 
the culture was infected with Influenza A H1N1/PR8/1934. After incubation at 33 °C for 72 hours, 
the culture was harvested and the influenza virus and hemagglutinin content analysed with a 
TCID50 assay, immunoblot and ELISA.  
In summary, the WAVE BIOREACTOR™ system was shown to be a versatile system for 
microcarrier cultivation of MDCK cells and a fast and convenient alternative for influenza 
production as compared to conventional stirred-tank reactors.  
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The currently available anti-pneumococcal vaccines are based on capsular polysaccharide (PS), 
plain or conjugated to a carrier protein. Conjugated vaccines are expensive products, especially 
in the case of pneumococcus, in which reasonable coverage requires from 7 to 13 serotypes. To 
obtain increased coverage with fewer components, we evaluated the immunogenicity of the 
Pneumococcal surface protein A (PspA), conjugated to capsular polysaccharide serotype 23F, 
aiming at induction of an immune response against both components. Mice immunized with 
PS23F-rPspA1 conjugate produced antibodies against both PS and rPspA1, comparable or 
slightly higher than that obtained by free PS. The immunized animals challenged with a lethal 
dose of a virulent strain bearing a homologous PspA, showed that the PS23F-rPspA1 conjugate 
induced higher survival than rPspA1 alone or in combination with PS. This increased protection 
was shown to correlate with the enhanced capacity of the antibodies to bind to the pneumococcal 
surface and to induce complement deposition. Our results indicate that the use of PS-PspA 
conjugates may be a way to increase coverage against pneumococci with fewer components.  
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Aims: To recommend safe dosing regimen for delivery of adenoviral vectored vaccines to 
humans. To identify potential target organs for toxicity to guide clinical safety monitoring plan. To 
identify potential toxicology parameters that would identify special populations who might be at 
risk of harm from product.  
Methods: Biodistribution of single i.m. injection of 0.89x1011 VP in rabbits of Adenovirus type 5 
(Ad5) vectored Ebola vaccine was determined. 5 animals/gender were sacrificed on Study Day 
(SD) 9, SD61, and SD93. Tissues were analyzed by quantitative PCR. Toxicological safety 
evaluations were performed on rabbits receiving repeated i.m. dosing of 1 or 2x1011 VP Ad5 
vectored Ebola vaccines alone or Ad5 vectored Marburg vaccine given as boost to 4 mg DNA 
plasmid priming series. 5 rabbits/gender sacrificed 2 days and 2 weeks post last injection. 
Parameters monitored were mortality, morbidity, body weight, food consumption, clinical 
pathology, body temperatures, ophthalmology, Draize reactogenicity scores, organ weight, and 
gross and histopathology.  
Results: The adenovectors remained primarily at sites of injection in muscle and subcutis and 
only trafficked to liver and spleen, but no other distal organs, including remaining absent in 
gonads. Over time, the number of animals with, and copy numbers present in positive tissues 
declined, demonstrating clearance of the adenovectors. Also, body temperatures were elevated 
and food consumption was diminished in the day(s) immediately after Ad5 inoculations. Some 
clinical pathology parameters were impacted. Reversible findings in Draize and histopathology at 
injection sites seen.  
Discussion: Biodistribution and toxicology studies demonstrate that the Ad5 vaccine candidates 
tested were safe and suitable for investigational clinical use. One of the Ad5 Ebola vaccines has 
entered clinical trials.  
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Influenza virus is one of the most important respiratory pathogens. In the United States alone, 
influenza infection (flu) is responsible for 20,000 to 40,000 deaths and over 100,000 
hospitalizations annually. Infants, the elderly, and individuals with compromised cardiac, 
pulmonary, or immune systems are at great risk of serious complications from this virus. 
Immunization proves to be the most effective measure in preventing infection; vaccines matched 
antigenically with the circulating viral strains have demonstrated up to 70-90% of efficacy in terms 
of protecting healthy adults from influenza illness [MMWR (2003);52 (No. RR-8)]. The 
conventional influenza vaccines are composed of inactivated viruses, administered as inactivated 
whole virions, split or purified viral sub-unit proteins. Recently, cold adapted live influenza 
vaccines have been licensed in the U.S. for use in populations 5 to 49 years of age. One of the 
common features shared by all current influenza vaccines is that the vaccines are targeted 
primarily to the induction of neutralizing antibodies directed against the major viral envelope 
protein, hemagglutinin (HA). Because HA can readily undergo mutation (antigenic drift), the 
vaccine formulations need to be evaluated on a yearly basis to match the current circulating 
strains, and accordingly, immunizations must be performed annually. This requirement imposes a 
significant burden on vaccine production and supply as well as on vaccination practice.  
 
A vaccine that can provide cross protection against different influenza variants or strains and that 
does not require frequent updates is highly desirable. Moreover, the immediate availability of 
such a vaccine in the setting of an influenza pandemic caused by a major antigenic shift would be 
an extremely valuable public health tool.  We'll present a novel strategy in the design of a 
"universal" conjugate influenza vaccine.  Early clinical data suggest the candidate vaccine is both 
safe and immunogenic.  
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As gene therapy progresses into clinical trials, full characterization of the viral vectors becomes 
an important issue. Retroviruses are known to acquire minute amounts of host cellular proteins 
that can be biologically active both on the surface and inside the virion. However, in spite of the 
widespread use of retroviral vectors both in experimental and clinical studies, the repertoire of 
host proteins incorporated into MoMLV vector particles remains unexplored. We have developed 
a rate zonal ultracentrifugation strategy that rendered highly purified retroviral vector preparations 
suitable for the study of the composition of retroviral vector particles. The high level of purity 
achieved by this method was demonstrated using a variety of techniques including 
electrophoretic analyses, size exclusion chromatography, subtilisin digestion and electron 
microscopy. Proteomic analysis of the purified virions was performed. Viral proteins were 
fractionated by 1D-SDS-PAGE, in-gel tryptic digested and subjected to liquid 
chromatography/tandem mass spectrometry analysis (LC-MS/MS). These studies led to the 
identification of 27 host proteins associated to retroviral particles derived from 293 HEK cells, 
including 5 proteins previously described as part of wild type MoMLV. Nineteen host proteins 
identified corresponded to intracellular proteins. A total of 8 host membrane proteins were 
identified including cell adhesion proteins integrin Î²1 (fibronectin receptor subunit beta) and MFG-
E8, tetraspanins CD81 and CD9 and late endosomal markers CD63 and Lamp-2. Immunogold 
electron microscopy studies confirmed the presence of several host membrane proteins exposed 
at the vector surface. Membrane proteins are particularly attractive since they can serve as 
anchoring sites for the insertion of tags for targeting or purification purposes. This work 
represents an important step forward in the elucidation of retroviral vector composition.  
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Determining influenza virus hemagglutinin (HA) concentration is critical for the final formulation of 
the vaccine and for manufacturing process development. The HA concentration is commonly 
determined by single radial immuno-diffusion assay (SRID) as recommended by the European 
Pharmacopoeia and WHO. However, the SRID assay has a number of disadvantages as it is 
laborious and has a low detection range inducing high variation. Thus, SRID is not an optimal 
method for neither batch release analysis of the vaccine nor in process development. Surface 
Plasmon Resonance (SPR) technology monitors the interactions of a molecule on the surface of 
a chip, and holds the potential of being a highly sensitive, less time consuming and more 
accurate methodology.  
 
In this study an analytical method using Biacore™ was developed with the goal of receiving a 
robust and accurate assay for three influenza virus types (A/H1N1, A/H3N2 and B) with lower 
detection limit than SRID (<5µg HA/ml). The robustness, accuracy, precision and detection range 
of the three influenza virus Biacore assays were investigated and compared to SRID analysis. It 
was found that the Biacore assay has high specificity, showing the potential of a future vaccine 
batch release assay.  
 
Furthermore, the assay was shown to have higher precision for in process samples and a higher 
detection range with a limit of detection ~1 log lower than SRID. Therefore, the Biacore assay is 
among the most compelling analytical tools in process development for influenza vaccines.  
 
